BYNFEZIA Drug Patent Profile
✉ Email this page to a colleague
When do Bynfezia patents expire, and what generic alternatives are available?
Bynfezia is a drug marketed by Sun Pharm and is included in one NDA. There are five patents protecting this drug.
The generic ingredient in BYNFEZIA is octreotide acetate. There are twenty drug master file entries for this compound. Fourteen suppliers are listed for this compound. Additional details are available on the octreotide acetate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Bynfezia
A generic version of BYNFEZIA was approved as octreotide acetate by WEST-WARD PHARMS INT on April 8th, 2005.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for BYNFEZIA?
- What are the global sales for BYNFEZIA?
- What is Average Wholesale Price for BYNFEZIA?
Summary for BYNFEZIA
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Drug Prices: | Drug price information for BYNFEZIA |
| DailyMed Link: | BYNFEZIA at DailyMed |
US Patents and Regulatory Information for BYNFEZIA
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sun Pharm | BYNFEZIA PEN | octreotide acetate | SOLUTION;SUBCUTANEOUS | 213224-001 | Sep 27, 2024 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Sun Pharm | BYNFEZIA PEN | octreotide acetate | SOLUTION;SUBCUTANEOUS | 213224-001 | Sep 27, 2024 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Sun Pharm | BYNFEZIA PEN | octreotide acetate | SOLUTION;SUBCUTANEOUS | 213224-001 | Sep 27, 2024 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Sun Pharm | BYNFEZIA PEN | octreotide acetate | SOLUTION;SUBCUTANEOUS | 213224-001 | Sep 27, 2024 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Sun Pharm | BYNFEZIA PEN | octreotide acetate | SOLUTION;SUBCUTANEOUS | 213224-001 | Sep 27, 2024 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
